ID   MM485
AC   CVCL_2610
SY   MM 485
DR   BioSample; SAMN07624433
DR   cancercelllines; CVCL_2610
DR   CBA; CBA-1355
DR   Cosmic; 889028
DR   Cosmic; 928728
DR   Cosmic; 1206009
DR   Cosmic; 2159428
DR   DepMap; ACH-001973
DR   ECACC; 11072803
DR   GEO; GSM170849
DR   GEO; GSM226724
DR   Progenetix; CVCL_2610
DR   Wikidata; Q54906150
RX   PubMed=1697409;
RX   PubMed=3127479;
RX   PubMed=7780963;
RX   PubMed=9354451;
RX   PubMed=9466661;
RX   PubMed=10070891;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=17516929;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp100Ter; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; DepMap).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): CBA; DepMap
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,13
ST   D16S539: 11
ST   D18S51: 13,17
ST   D19S433: 12,14
ST   D21S11: 30
ST   D2S1338: 17,20
ST   D3S1358: 14
ST   D5S818: 11,12
ST   D7S820: 12
ST   D8S1179: 11,13
ST   FGA: 21,23
ST   Penta D: 10,12
ST   Penta E: 10,15
ST   TH01: 8
ST   TPOX: 9,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=1697409;
RA   Chenevix-Trench G., Martin N.G., Ellem K.A.O.;
RT   "Gene expression in melanoma cell lines and cultured melanocytes:
RT   correlation between levels of c-src-1, c-myc and p53.";
RL   Oncogene 5:1187-1193(1990).
//
RX   PubMed=3127479; DOI=10.1111/1523-1747.ep12461022;
RA   McEwan M., Parsons P.G., Moss D.J.;
RT   "Monoclonal antibody against human tyrosinase and reactive with
RT   melanotic and amelanotic melanoma cells.";
RL   J. Invest. Dermatol. 90:515-519(1988).
//
RX   PubMed=7780963;
RA   Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A.,
RA   Toso R.J., Herlyn M., Bennett D.C.;
RT   "Protein B61 as a new growth factor: expression of B61 and
RT   up-regulation of its receptor epithelial cell kinase during melanoma
RT   progression.";
RL   Cancer Res. 55:2528-2532(1995).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=9466661; DOI=10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D;
RA   White C.A., Thomson S.A., Cooper L., van Endert P.M., Tampe R.,
RA   Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.;
RT   "Constitutive transduction of peptide transporter and HLA genes
RT   restores antigen processing function and cytotoxic T cell-mediated
RT   immune recognition of human melanoma cells.";
RL   Int. J. Cancer 75:590-595(1998).
//
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//